The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration

Alon Harris, T. A. Ciulla, L. M. Pratt, E. Rechtman, L. Kagemann, H. C. Piper, H. J. Garzozi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD). Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography (FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months. Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions (p=0.007, p=0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas (p=0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times (p=0.19). Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.

Original languageEnglish
Pages (from-to)753-757
Number of pages5
JournalBritish Journal of Ophthalmology
Volume87
Issue number6
DOIs
StatePublished - Jun 1 2003

Fingerprint

dorzolamide
Macular Degeneration
Perfusion
Ophthalmoscopes
Fluorescein Angiography
Lasers
Fluorescence
Placebos
Indicator Dilution Techniques
Retinal Vessels
Indocyanine Green
Temporal Lobe
Double-Blind Method
Angiography

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration. / Harris, Alon; Ciulla, T. A.; Pratt, L. M.; Rechtman, E.; Kagemann, L.; Piper, H. C.; Garzozi, H. J.

In: British Journal of Ophthalmology, Vol. 87, No. 6, 01.06.2003, p. 753-757.

Research output: Contribution to journalArticle

Harris, Alon ; Ciulla, T. A. ; Pratt, L. M. ; Rechtman, E. ; Kagemann, L. ; Piper, H. C. ; Garzozi, H. J. / The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration. In: British Journal of Ophthalmology. 2003 ; Vol. 87, No. 6. pp. 753-757.
@article{d86fef0fac1a49b5a94c546aab99bf42,
title = "The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration",
abstract = "Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD). Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography (FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months. Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions (p=0.007, p=0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas (p=0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times (p=0.19). Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.",
author = "Alon Harris and Ciulla, {T. A.} and Pratt, {L. M.} and E. Rechtman and L. Kagemann and Piper, {H. C.} and Garzozi, {H. J.}",
year = "2003",
month = "6",
day = "1",
doi = "10.1136/bjo.87.6.753",
language = "English",
volume = "87",
pages = "753--757",
journal = "British Journal of Ophthalmology",
issn = "0007-1161",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - The effects of dorzolamide on choroidal and retinal perfusion in non-exudative age related macular degeneration

AU - Harris, Alon

AU - Ciulla, T. A.

AU - Pratt, L. M.

AU - Rechtman, E.

AU - Kagemann, L.

AU - Piper, H. C.

AU - Garzozi, H. J.

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD). Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography (FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months. Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions (p=0.007, p=0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas (p=0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times (p=0.19). Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.

AB - Aim: To comprehensively evaluate the effects of dorzolamide on the choroidal and retinal circulation in patients with age related macular degeneration (AMD). Methods: In this randomised, double masked, parallel study, 36 non-exudative AMD patients were randomised in a 2 to 1 fashion to placebo versus topical dorzolamide and underwent assessment of their choroidal and retinal circulation. Scanning laser ophthalmoscope indocyanine green angiograms (ICGA) were analysed by a new area dilution analysis technique. Four areas in the perifoveal region and two areas in the temporal peripapillary region were evaluated by plotting intensity of fluorescence of each area over time. The means of the choroidal filling times and the heterogeneity of the filling times were assessed. Scanning laser ophthalmoscope fluorescein angiography (FA) was evaluated for retinal arteriovenous passage (AVP) times by plotting intensity of fluorescence of retinal vessels over time. Assessment was performed at baseline and at 4 months. Results: Compared to placebo, AMD patients treated with dorzolamide showed a significantly increased rapidity of choroidal filling in the superior and inferior peripapillary regions (p=0.007, p=0.02, respectively). No significant difference in choroidal filling times was found in any of the perifoveal areas (p=0.9). Also, on FA assessment, treatment with dorzolamide showed no statistical differences in AVP times (p=0.19). Conclusions: Dorzolamide may increase peripapillary choroidal perfusion in non-exudative AMD patients. Further studies are merited.

UR - http://www.scopus.com/inward/record.url?scp=0038694680&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038694680&partnerID=8YFLogxK

U2 - 10.1136/bjo.87.6.753

DO - 10.1136/bjo.87.6.753

M3 - Article

VL - 87

SP - 753

EP - 757

JO - British Journal of Ophthalmology

JF - British Journal of Ophthalmology

SN - 0007-1161

IS - 6

ER -